Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 44Carboplatin 28Cisplatin 26Paclitaxel 24Bevacizumab 21human papillomavirus vaccine, L1 type 16, 18 16Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14atezolizumab 11Papillomavirus Vaccines 11Nivolumab 10tisotumab vedotin 8Vaccines, Synthetic 8Gemcitabine 8Colposcopy 8Topotecan 7fludarabine 6Vaccines 6Injections 6Cyclophosphamide 6spartalizumab 5balstilimab 5Pemetrexed 5Irinotecan 5Fulvestrant 5Docetaxel 5zimberelimab 4durvalumab 4Vinorelbine 4Ipilimumab 4Interleukin-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Uterine Cervical Neoplasms × MEDI0457 × Clear all
NCT02172911 2021-02-21

A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

Inovio Pharmaceuticals

Phase 1/2 Completed
10 enrolled 19 charts
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡